Diabetes, gestational diabetes and the risk of cancer in women: Epidemiologic evidence and possible biologic mechanisms

Women's Health

Volumn 7, Issue 2, 2011, Pages 227-237

  Chodick, Gabriel ^a,b   Zucker, Inbar ^a,b,c  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MINISTRY OF HEALTH   (Israel)

Author keywords

cancer; diabetes; insulin; meta analysis; women

Indexed keywords

INSULIN; SEX HORMONE; SOMATOMEDIN C;

AGING; BLADDER CANCER; BODY MASS; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; DIETARY INTAKE; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; LIFESTYLE; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OXIDATIVE STRESS; PANCREAS CANCER; PREGNANCY DIABETES MELLITUS; REVIEW; RISK FACTOR; SEX DIFFERENCE;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; HUMANS; NEOPLASMS; PREGNANCY; RISK FACTORS;

EID: 79952781859     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.4     Document Type: Review

References (87)

1. Jemal A, Siegel R, Xu R, Ward E: Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Kessler I: Cancer and diabetes mellitus. A review of the literature. J. Chronic Dis. 23, 579-600 (1971).
3. Kessler I: Cancer mortality among diabetics. J. Natl Cancer Inst. 44, 673-686 (1970).
4. Giovannucci E, Harlan D, Archer M et al.: Diabetes and cancer: a consensus report. CA Cancer J. Clin. 60, 207-221 (2010).
5. Vigneri P, Frasca F, Siacca L, Pandini G: Diabetes and cancer. Endocr. Relat. Cancer 16, 1103-1123 (2009).
6. Thevenod F: Pathophysiology of diabetes mellitus Type 2: role of obesity, insulin resistance and β-cell dysfunction. In: Diabetes and Cancer:Epidemiological Evidence and Molecular Links. Masur K, Thevenod F, Zanker K (Eds). Karger, Basel, Switzerland (2008).
7. Frasca F, Pandini G, Scalia P et al.: Insulin receptor isoform A, a newly recognized, high-affnity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 19, 3278-3288 (1999). (Pubitemid 29193789)
8. Nicolucci A: Epidemiological aspects of neoplasms in diabetes. Acta Diabetol. 47, 87-95 (2010).
9. Riedemann J, Macaulay V: IGF1R signalling and its inhibition. Endocr. Relat. Cancer 13(Suppl. 1), S33-S43 (2006). (Pubitemid 46219247)
10. Godsland I: Insulin resistance and hyperinsulinemia in the development and progression of cancer. Clin. Sci. (Lond.) 118, 315-332 (2010).
11. Werner H, Maor S: The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol. Metab. 17, 236-242 (2006). (Pubitemid 44080616)
12. Neuhausen S, Brummel S, Ding Y et al.: Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. 11, R76 (2009).
13. Dranzin B: Mitogenic action of insulin: friend, foe or 'frenemy'. Diabetologia 53, 229-233 (2010).
14. Ding E, Dong Y, Malik V, Liu S: Sex differences of endogenous sex hormonesand risk of Type 2 diabetes. JAMA 295, 1288-1299 (2006).
15. Wolf I, Rubinek T: Diabetes mellitus and breast cancer. In: Diabetes and Cancer Epidemiological Evidence and Molecular Links. Masur K, Thvenod F, Zanker KS (Eds). Karger, Basel, Switzerland, 97-113 (2008).
16. Papioannou S, Tzafettas J: Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinemia as promoters of endometrial and breast cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 24, 19-27 (2010).
17. Gunter M, Hoover D, Yu H et al.: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women J. Natl Cancer Inst. 101, 48-60 (2009).
18. Teede H, Deeks A, Moran A: Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41 (2010).
19. Chittenden B, Fullerton G, Maheshwari A, Bhattacharya S: Polycystic ovary syndrome and the risk ofgynaecological cancer: a systematic review. Reprod. Biomed. Online 19, 398-405 (2009).
20. Krone C, Ely J: Controlling hyperglycemia as an adjunct to cancer therapy. Integr. Cancer Ther. 4, 25-31 (2005). (Pubitemid 40250675)
21. Chandrasekaran K, Swaminathan K, Chatterjee S, Dey A: Apoptosis in hepG2 cells exposed to high glucose. Toxicol. In Vitro 24, 387-396 (2010).
22. Zhang Y, Zhou J, Wang T, Cai T: High level glucose increases mutagenesis in human lymphoblastoid cells. Int. J. Biol. Sci. 3, 275-279 (2007).
23. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S: Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch. Intern. Med. 166, 1871-1877 (2006). (Pubitemid 44455170)
24. Chodick G, Heymann A, Rosenmann L et al.: Diabetes and risk of incident cancer: a large population-based cohort studyin Israel. Cancer Causes Control 21, 879-887 (2010).
25. Pickup J: Infammation and activated innate immunity in the pathogenesis of Type 2 diabetes. Diabetes Care 27, 813-823 (2004). (Pubitemid 38280558)
26. Cooke CB, Gately PJ: Physical activity, obesity, and Type 2 diabetes. In: Obesity and Diabetes (2nd Edition). Barnett A, Kumar S (Eds). Wiley-Blackwell, Chippenham, Wiltshire, UK (2009).
27. Bernstein L, Lu Y, Henderson K: Physical activity and cancer. In: Cancer and Energy Balance, Epidemiology and Overview. Berger N (Ed.). Springer, NY, USA (2010).
28. Steinbrecher A, Erber E, Grandinetti A, Kolonel L, Maskarinec G: Meat consumption and risk of Type 2 diabetes: the Multiethnic Cohort. Public Health Nutr. doi: 10.1017/S1368980010002004 (2010) (Epub ahead of print).
29. Barclay A, Petocz P, McMillan-Price J et al.: Glycemic index, glycemicload, and chronic disease risk-a meta-analysis of observational studies. Am. J. Clin. Nutr. 627, 687-637 (2008).
30. Hirohata T, Kono S: Diet/nutrition and stomach cancer in Japan. Int. J. Cancer Suppl. 10, 34-36 (1997).
31. Chao C, Page J: Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis. Am. J. Epidemiol. 168, 471-480 (2008).
32. Chari S, Leibson C, Rabe K, Ransom J, de Andrade M, Petersen G: Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129, 504-511 (2005). (Pubitemid 41096638)
33. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M: Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92, 2076-2083 (2005). (Pubitemid 40897433)
34. Stevens R, Roddam A, Spencer E et al.; Million Women Study Collaborators: Factors associated with incident and fatal pancreatic cancer in a cohort of middle-aged women. Int. J. Cancer 124, 2400-2405 (2009).
35. El-Serag H, Hampel H, Javadi F: The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 4, 369-380 (2006). (Pubitemid 43343895)
36. Fujino Y, Mizoue T, Tokui N, Yoshimura T: Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab. Res. Rev. 17, 374-379 (2001). (Pubitemid 33040310)
37. Hassan M, Hwang L, Hatten C, Swaim M, Li D, Abbruzzese J: Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36, 1206-1213 (2002). (Pubitemid 35253437)
38. Davila J, Morgan R, Shaib Y, McGlynn K, El-Serag H: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study Gut 54, 533-539 (2005). (Pubitemid 40403031)
39. Larsson S, Orsini N, Wolk A: Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J. Natl Cancer Inst. 97, 1679-1687 (2005). (Pubitemid 41672234)
40. Campbell P, Deka A, Jacobs E et al.: Prospective study reveals associations between colorectal cancer and Type 2 diabetes mellitus or insulin use in men. Gastroenterology 139(4), 1138-1146 (2010).
41. Kuriki K, Hirose K, Tajima K: Diabetes and cancer risk for all and specifc sites among Japanese men and women. Eur. J. Cancer Prev. 16, 83-89 (2007). (Pubitemid 46105011)
42. Limburg P, Vierkant R, Fredericksen Z: Clinically confrmed Type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am. J. Gastroenterol. 101, 1872-1879 (2006). (Pubitemid 44166600)
43. Seow A, Yuan J, Koh W, Lee H, Yu M: Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J. Natl Cancer Inst. 98, 135-138 (2006). (Pubitemid 43159968)
44. Oliveria S, Koro C, Yood MU, Sowell M: Cancer incidence among patients treated with antidiabetic pharmacotherapy Diabetes Metab. Syndr. Clin. Res. Rev. 2, 47-57 (2008). (Pubitemid 351194192)
45. Cohen F, Neslusan C, Conklin J, Song X: Recent antihyperglycemic prescribing trends for US privately insured patients with Type 2 diabetes. Diabetes Care 26, 1847-1851 (2003). (Pubitemid 36929131)
46. Hoerger T, Segel J, Gregg E, Saaddine J: Is glycemic control improving in US adults? Diabetes Care 31, 81-86 (2008).
47. Larsson S, Orsini N, Brismar K, Wolk A: Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49, 2819-2823 (2006). (Pubitemid 44730282)
48. Tripathi A, Folsom A, Anderson K: Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women's Health Study. Cancer 95, 2316-2323 (2002). (Pubitemid 35351137)
49. Swerdlow A, Laing S, Qiao Z et al.: Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br. J. Cancer 92, 2070-2075 (2005). (Pubitemid 40897432)
50. Friberg E, Orsini N, Mantzoros C, Wolk A: Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50, 1365-1374 (2007). (Pubitemid 46879010)
51. Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A: Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br. J. Cancer 98, 1582-1585 (2008). (Pubitemid 351652323)
52. Saltzman B, Doherty J, Hill D et al.: Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am. J. Epidemiol. 167, 607-614 (2008). (Pubitemid 351323306)
53. Crave J, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M: Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J. Clin. Endocrinol. Metab. 80, 2057-2062 (1995).
54. Modugno F, Ness R, Chen C, Weiss N: Infammation and endometrial cancer: a hypothesis. Cancer Epidemiol. Biomarkers Prev. 14, 2840-2847 (2005).
55. Lisker S, Brody J, Beizer L: Abnormal carbohydrate metabolism in patients with malignant blood dyscrasias. Am. J. Med. Sci. 252, 282-288 (1966).
56. Mitri J, Castillo J, Pittas A: Diabetes and risk of non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care 31, 2391-2397 (2008).
57. Cerhan J, Wallace R, Folsom A et al.: Medical history risk factors for non-Hodgkin's lymphoma in older women. J. Natl Cancer Inst. 89, 314-318 (1997). (Pubitemid 27085894)
58. Larsson S, Mantzoros C, Wolk A: Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer 121, 856-862 (2007). (Pubitemid 47106217)
59. Ferrara A: Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care 30(Suppl. 2), S141-S146 (2007). (Pubitemid 47036416)
60. Kjos S, Buchanan T: Gestational diabetes mellitus. N. Engl. J. Med. 341(23), 1749-1756 (1999).
61. Nechuta S, Paneth N, Velie E: Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature. Cancer Causes Control 21(7), 967-989 (2010).
62. Perrin M, Terry M, Kleinhaus K et al.: Gestational diabetes as a risk factorfor pancreatic cancer: a prospective cohort study. BMC Med. 5, 25 (2007).
63. Li D, Abbruzzese J: New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin. Cancer Res. 16, 4313-4318 (2010).
64. Troisi R, Weiss H, Hoover R: Pregnancy characteristics and maternal risk of breast cancer. Epidemiology 9, 641-647 (1998). (Pubitemid 28476126)
65. Dawson S: Long-term risk of malignant neoplasm associated with gestational glucose intolerance. Cancer Causes Control 100, 149-155 (2004). (Pubitemid 37553550)
66. Rollison D, Sellers T, Laronga C et al.: Population-based case-control study of diabetes and breast cancer risk in Hispanic and non-Hispanic White women living in US southwestern states. Am. J. Epidemiol. 167, 447-456 (2008). (Pubitemid 351264144)
67. Jee S, Ohrr H, Sull J, Yun J, Ji M, Samet J: Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293(2), 194-202 (2005). (Pubitemid 40095870)
68. Rapp K, Schroeder J, Klenk J et al.: Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria Diabetologia 49, 945-952 (2006).
69. Stattin P, Bjor O, Ferrari P et al.: Prospective study of hyperglycemia and cancer risk. Diabetes Care 30, 561-567 (2007). (Pubitemid 46354334)
70. Shalev V, Chodick G, Bialik M, Green M, Heymann A: In a population-based cohort of diabetes patients, men and women had similar risks for all-cause mortality. J. Clin. Epidemiol. 60, 86-93 (2007). (Pubitemid 44856242)
71. Biderman A, Rosenblatt I, Rosen S et al.: Sex differentials in predictors of mortality for patients with adult-onset diabetes: a population-based follow-up study in Beer-Sheva, Israel. Diabetes Care 23, 602-605 (2000). (Pubitemid 30321537)
72. Yancik R, Wesley M, Ries L, Havlik R, Edwards B, Yates J: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285, 885-892 (2001). (Pubitemid 32171549)
73. Orchard T: The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann. Med. 28, 323-333 (1996). (Pubitemid 26268251)
74. Shalev V, Chodick G, Heymann A, Kokia E: Gender differences in healthcare utilization and medical indicators among patients with diabetes. Public Health Nutr. 119, 45-49 (2005). (Pubitemid 39618429)
75. Meyerhardt J, Catalano P, Haller D et al.: Impact of diabetes mellitus on outcomes in patients with colon cancer. J. Clin. Oncol. 21, 433-440 (2003). (Pubitemid 46606471)
76. Van de Poll-Franse L, Houterman S, Janssen-Heijnen M, Dercksen M, Coebergh J, Haak H: Less aggressive treatment and worse overallsurvival in cancer patients with diabetes: a large population based analysis. Int. J. Cancer 1986-1992 (2007). (Pubitemid 46418378)
77. Rose D, Komninou D, Stephenson G: Obesity, adipocytokines and insulin resistance in breast cancer. Obes. Rev. 5, 153-165 (2004). (Pubitemid 38998240)
78. Catalano S, Mauro L, Marsico S et al.: Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J. Biol. Chem. 279, 19908-19915 (2004). (Pubitemid 38623433)
79. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M: Adiponectin and breast cancer risk. J. Clin. Endocrinol. Metab. 89, 1102-1007 (2004).
80. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C: Plasma adiponectin concentration in relation to endometrial cancer: a case-control study in Greece. J. Clin. Endocrinol. Metab. 88, 993-997 (2003). (Pubitemid 36337745)
81. Pechlivanis S, Bermejo J, Pardini B et al.: Genetic variation in adipokine genes and risk of colorectal cancer. Eur. J. Endocrinol. 160, 933-940 (2009).
82. Evans J, Donnelly L, Emslie-Smith A, Alessi D, Morris A: Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305 (2005). (Pubitemid 40813563)
83. Currie C, Poole C, Gale E: The infuence of glucose-lowering therapies on cancer risk in Type 2 diabetes. Diabetologia 52, 1766-1777 (2009).
84. Hemkens LG, Grouven U, Bender R et al.: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52, 1732-1744 (2009).
85. Colhoun H, SDRN Epidemiology Group: Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52, 1755-1765 (2009).
86. Jonasson J, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G: Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52, 1745-1754 (2009).
87. Cantrell LA, Zhou C, Mendivil A, Maloy K, Gehrig P, Bae-Jump V: Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol. Oncol. 116, 92-98 (2010).